Cargando…
Two Faces of Catechol-O-Methyltransferase Inhibitor on One-Carbon Metabolism in Parkinson’s Disease: A Meta-Analysis
Levodopa (L-dopa) and catechol-O-methyltransferase (COMT) inhibition are widely used therapeutics in Parkinson’s disease (PD). Despite their therapeutic effects, it was raised that nutrients involved in one-carbon metabolism can be deteriorated by PD therapies. The aim of this meta-analysis was to i...
Autores principales: | Kim, Jin Hee, Jin, Shaoyue, Eo, Hyeyoon, Oh, Myung Sook, Lim, Yunsook |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964466/ https://www.ncbi.nlm.nih.gov/pubmed/36839259 http://dx.doi.org/10.3390/nu15040901 |
Ejemplares similares
-
Similarities and differences between alpha-tocopherol and gamma-tocopherol in amelioration of inflammation, oxidative stress and pre-fibrosis in hyperglycemia induced acute kidney inflammation
por: Shin, Hanna, et al.
Publicado: (2016) -
Roles of functional catechol-O-methyltransferase genotypes in Chinese patients with Parkinson’s disease
por: Xiao, Qin, et al.
Publicado: (2017) -
Design, synthesis and evaluation of 3-hydroxypyridin-4-ones as inhibitors of catechol-O-methyltransferase
por: de Beer, Johannie, et al.
Publicado: (2020) -
Catechol‐O‐Methyltransferase and Cardiovascular Disease: MESA
por: Hall, Kathryn T., et al.
Publicado: (2019) -
Depression and Catechol-O-methyltransferase (COMT) genetic variants are associated with pain in Parkinson’s disease
por: Lin, Chin-Hsien, et al.
Publicado: (2017)